For #WorldHormoneDay, we spotlight hypoparathyroidism, a condition with insufficient production of hormone PTH. Innovations like Yorvipath, Eneboparatide, Canvuparatide, and $ENTX EB612 oral PTH (1-34) offer hope. The future’s bright! #BecauseHormonesMatter

May is #OsteoporosisAwarenessMonth! This "silent disease" weakens bones, raising fracture risk. Prioritize early detection, calcium, vitamin D, exercise & screenings. $ENTX EB613 in development to be the first oral anabolic treatment. Protect your #bonehealth!

Last week, $ENTX announced a business update for first quarter 2025. investors.enterabio.com/news-releases/…

Venture capital funding for women's health hit a new high last year, but federal policy upheaval could stymie research & innovation. Read full article here: biopharmadive.com/news/womens-he…

Osteoporosis risks rise after 50, but bone health starts now! Eat well, exercise, and skip smoking/alcohol to prevent this serious disease, whether you're 25 or 75. #BoneHealth #Osteoporosis sheknows.com/health-and-wel…

Osteoporosis isn't just for older adults. British runner Bobby Clay was diagnosed at 18 due to overtraining & under-fueling, leading to RED-S. Her story stresses proper nutrition & hormonal health in youth sports. Hear more on the Olympic website: olympics.com/en/video/podca…

Oral OXM, a GLP-1/Glucagon dual agonist tablet, targets obesity & metabolic disorders. Preclinical trials show strong systemic exposure & PK profile, consistent with oral semaglutide's half-life. IND filing expected late-2025 with $OPK $ENTX

Osteoporosis affects 27% of U.S. women over 65, vs. 6% of men, increasing fracture risk. Menopause accelerates bone loss. Screen at 65, or earlier with risk factors. Exercise, calcium, vitamin D, and avoiding smoking/alcohol help. sciencenews.org/article/bone-h…

GLP-1 weight loss drugs like Ozempic & Wegovy may increase osteoporosis risk, as 40% of weight loss is muscle & bone mass, per Univ. of Liverpool study. ROS warns of brittle bone risk. Full story: diabetes.co.uk/news/2025/jun/…

AMWA's osteoporosis hub educates clinicians & public on this "silent" disease. Learn prevention via nutrition, exercise, lifestyle & screening. Discover risk factors & why early detection matters amwa-doc.org/our-work/initi…

50+ trials with 170,000 patients show hip BMD increase over 24 months predicts fracture risk reduction. STEs: 1.43% for vertebral, 2.04% for clinical, 2.13% for non-vertebral, 3.07% for hip fractures. The FDA is reviewing BMD as surrogate endpoint for new osteoporosis drugs.

Menopause isn’t a time to shrink back, it’s a time to stand in your power, with strength from the inside out. What every woman needs to know about bone loss during menopause! Article by Dr. Marva Williams (Hons) on Elysium Lifestyle Magazine elysiumlifestylemagazine.com/standing-tall-… #osteoporosis

$ENTX $OPK to present oral OPK-88006 data at ENDO 2025. Dual GLP-1/glucagon agonist tablet targets obesity & metabolic disorders. FDA IND filing planned for 2025, with Phase 1 being planned. Details: investors.enterabio.com/news-releases/…

$ENTX EB613, a daily oral PTH(1-34) tablet, boosts BMD in postmenopausal women with osteoporosis. Randomized Phase 2 data on 161 women shows dual action on bone formation & resorption. 3D-DXA analysis to be presented at ASBMR 2025. investors.enterabio.com/news-releases/…

Reduce osteoporosis risk early! In your 20s, build bone mass with calcium (1,000–1,200 mg/day), vitamin D (600–800 IU), and weight-bearing exercise 3–4x/week. Avoid smoking, limit alcohol, stay healthy. Women under 65 with risks: get bone density scans. self.com/story/how-to-p…

New in-vivo PK and PD data on a dual GLP-1/glucagon agonist oral tablet for obesity & metabolic disorders, to be presented at ENDO 2025 (July 12–15, SF). Developed by $ENTX $OPK investors.enterabio.com/news-releases/…

$ENTX $OPK oral GLP-2 analog for short bowel syndrome (SBS) to be presented at ESPEN 2025, Prague (Sep 13–16). Combines OPKO’s long-acting agonist with Entera’s N-Tab™ tech, offering a daily tablet alternative to daily injections. investors.enterabio.com/news-releases/…

$ENTX EB613, an oral anabolic tablet for osteoporosis, gets FDA agreement for phase 3 study with hip BMD as primary endpoint. Aiming to address unmet needs for 200M+ women, it could be the 1st daily oral treatment to boost bone mass & reduce fractures. investors.enterabio.com/news-releases/…

$ENTX Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates Read the Full News Release 👉 globenewswire.com/news-release/2…

$ENTX Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences Read the Full News Release 👉 globenewswire.com/news-release/2…